Benzinga | Mar 9, 2021 06:16AM EST

HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $43

HC Wainwright & Co. analyst Andrew Fein maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $60 to $43.